This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Vanda Pharmaceuticals Says Second Phase 3 Study of Tradipitant in Motion Sickness Yields 'Positive' Results MT
Vanda Pharmaceuticals Inc. Reports Positive Results from A Second Phase III Study of Tradipitant in Motion Sickness CI
Transcript : Vanda Pharmaceuticals Inc., Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q1 Revenue $47.5M MT
Vanda Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Sector Update: Health Care Stocks Advance in Late Afternoon Trading MT
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading MT
Sector Update: Health Care MT
Vanda Pharmaceuticals Shares Rise After Future Pak Adds $260 Million Potential Payments to Cash Offer MT
Future Pak sweetens buyout offer for Vanda Pharmaceuticals RE
Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer RE
Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court MT
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents RE
Butler Hall Capital urges Vanda to engage in sales discussions RE
Deals of the day-Mergers and acquisitions RE
Sector Update: Health Care Stocks Retreating Late Afternoon MT
Sector Update: Health Care Stocks Mixed Wednesday Afternoon MT
Sector Update: Health Care MT
Top Midday Gainers MT
Vanda Pharmaceuticals Adopts Stockholder Rights Plan; Shares Rise MT
Vanda Pharmaceuticals' Board Rejects all Unsolicited Takeover Proposals From Future Pak MT
Vanda Pharmaceuticals rejects takeover proposal from Future Pak RE
Traders Digest Earnings After Rate-Driven Losses, US Equity Futures Rebound Slightly MT
Top Premarket Gainers MT
Vanda Pharmaceuticals Gets Acquisition Proposal From Future Pak; Shares Rise Pre-Bell MT
Chart Vanda Pharmaceuticals Inc.
More charts
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
5.48 USD
Average target price
5.21 USD
Spread / Average Target